OMEROS CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
OMEROS CORP (OMER) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $4.26 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.70, a 43.40% decline year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $10.07, a 27.31% increase year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.91, a 26.62% decline year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $10.78, a 24.56% decline year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $10.15, a 3.70% decline from fiscal 2024.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $10.54, a 5.82% increase from fiscal 2023.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $9.96, a 17.34% decline from fiscal 2022.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $12.05.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.26 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $5.70 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $10.15 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $9.89 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $14.20 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $10.07 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $10.54 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $6.91 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $6.83 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $7.91 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $9.96 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $10.12 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $10.46 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $10.78 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $12.05 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $13.58 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $13.96 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $14.29 10-Q · filed 2022-05-10 | |||
| 2021-09-30 | $14.97 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $15.42 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |